MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?

MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?

Danielle Brazel,1 Misako Nagasaka2,3 1Department of Hematology/Oncology, Scripps Clinic/Scripps Green Hospital, La Jolla, CA, USA; 2Department of Hematology/Oncology, University of California Irvine School of Medicine, Chao Family Cancer Center, Orange, CA, USA; 3Department of Medicine, St. Marianna...

Full description

Bibliographic Details
Main Authors:	Brazel D, Nagasaka M
Format:	Article
Language:	English
Published:	Dove Medical Press 2024-04-01
Series:	Lung Cancer: Targets and Therapy
Subjects:	epidermal growth factor receptor (egfr) mutations first line treatment bispecific antibody
Online Access:	https://www.dovepress.com/mariposa-can-amivantamab-and-lazertinib-replace-osimertinib-in-the-fro-peer-reviewed-fulltext-article-LCTT

Similar Items

The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions
by: Kaakour D, et al.
Published: (2024-04-01)

The development of amivantamab for the treatment of non-small cell lung cancer
by: Danielle Brazel, et al.
Published: (2023-10-01)

Landmark PALOMA and MARIPOSA Studies Reveal the Impact of Amivantamab Alone and Combined with Lazertinib in Advanced NSCLC
by: Hiba Mechahougui, et al.
Published: (2024-06-01)

A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib
by: Arturo Simoni-Nieves, et al.
Published: (2024-09-01)

Amivantamab: A narrative drug review
by: Anupa John, et al.
Published: (2023-01-01)

Structural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies
by: Nishant Mohan, et al.
Published: (2024-05-01)

Structural Analysis of Interactions between Epidermal Growth Factor Receptor (EGFR) Mutants and Their Inhibitors
by: Yingzhe Guo, et al.
Published: (2023-03-01)

Co-targeting cancer stem-like cells and bulk cancer cells with a bispecific antibody
by: Shi Hu
Published: (2017-05-01)

Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for <i>EGFR</i> Mutation-Positive Patients Treated with First-Line Osimertinib
by: Amanda Jane Williams Gibson, et al.
Published: (2024-04-01)

Early onset venous and arterial thrombosis when combining Osimertinib and Amivantamab in NSCLC: Instructive cases and literature review
by: Alexander S Watson, et al.
Published: (2025-03-01)

Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications
by: Nina Shaban, et al.
Published: (2023-12-01)

Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer
by: Yaoyao LIU, et al.
Published: (2023-12-01)

eIg-based bispecific T-cell engagers targeting EGFR: Format matters
by: Lennart Kühl, et al.
Published: (2023-12-01)

Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma
by: Alan W Long, et al.
Published: (2024-04-01)

Real‐world study of lazertinib as second‐line or greater treatment in advanced non‐small cell lung cancer
by: Jeong Uk Lim, et al.
Published: (2024-07-01)

Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India
by: Atul Tiwari, et al.

Cluster analysis of deterioration sites after first-line epidermal growth factor receptor-tyrosine kinase inhibitor in epidermal growth factor receptor mutated non-small cell lung cancer
by: Shinichiro Okauchi, et al.
Published: (2022-06-01)

Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
by: Nami Tateyama, et al.
Published: (2022-11-01)

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
by: Ammelie Svea Boje, et al.
Published: (2024-12-01)

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors
by: Felix Oh, et al.
Published: (2020-06-01)

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an <i>EGFR</i>-Activating Mutation
by: Shigetoshi Nishihara, et al.
Published: (2022-07-01)

Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations
by: Yuki Takeyasu, MD, et al.
Published: (2024-02-01)

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
by: Jing Zhang, et al.
Published: (2025-02-01)

Successful Treatment with Osimertinib Based on Therapeutic Drug Monitoring in a Hemodialysis Patient with Non-Small Cell Lung Cancer: A Case Report
by: Keisuke Tabata, et al.
Published: (2023-08-01)

The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases
by: Peyton High, et al.
Published: (2024-07-01)

miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44
by: Shang-Gin Wu, et al.
Published: (2024-03-01)

Genomic evolutional analysis of surgical resected specimen to assess osimertinib as a first‐line therapy in two patients with lung cancer harboring EGFR mutation: Case series
by: Hayato Koba, et al.
Published: (2024-03-01)

Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms
by: Xin Liao, et al.
Published: (2024-10-01)

The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience
by: Ningning Yan, et al.
Published: (2024-02-01)

Shortened Hinge Design of Fab x sdAb-Fc Bispecific Antibodies Enhances Redirected T-Cell Killing of Tumor Cells
by: Shuyu Huang, et al.
Published: (2022-09-01)

Corrigendum: The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience
by: Ningning Yan, et al.
Published: (2024-06-01)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
by: Roa Alsajjan, et al.
Published: (2023-09-01)

Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trialResearch in context
by: Si-Yang Maggie Liu, et al.
Published: (2023-10-01)

Amelioration of Glioblastoma Multiforme via the Combination of Simulated Microgravity and Oncolytic Viral Therapy
by: Tarek Elshourbagy, et al.
Published: (2023-03-01)

A rare case of double primary lung adenocarcinomas with uncommon complex EGFR G719X and S768I mutations and pleomorphic carcinoma
by: Toshiki Morimoto, et al.
Published: (2023-10-01)

Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study
by: Hirotsugu Kenmotsu, MD, PhD, et al.
Published: (2024-11-01)

Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients
by: Piyada Sitthideatphaiboon, et al.
Published: (2025-01-01)

Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease
by: Molly S.C. Li, M.B.B.S., et al.
Published: (2024-04-01)

Engineering of a Bispecific Nanofitin with Immune Checkpoint Inhibitory Activity Conditioned by the Cross-Arm Binding to EGFR and PDL1
by: Perrine Jacquot, et al.
Published: (2023-03-01)

Anti‐epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma
by: Chen Chen, et al.
Published: (2020-03-01)